Cellid Co., Ltd. Logo

Cellid Co., Ltd.

Develops immunotherapeutic vaccines for cancer and infectious diseases.

299660 | KO

Overview

Corporate Details

ISIN(s):
KR7299660001
LEI:
Country:
South Korea
Address:
서울시 관악구 관악로 1 서울대학교 142동 5층, 서울시

Description

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean HTML 4.1 KB
2025-09-18 00:00
소송등의제기ㆍ신청(일정금액이상의청구)
Korean HTML 8.3 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean HTML 1015.8 KB
2025-08-12 00:00
소송등의판결ㆍ결정(일정금액이상의청구)
Korean HTML 7.0 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean HTML 28.4 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean HTML 25.5 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean HTML 25.5 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean HTML 25.5 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean HTML 27.6 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean HTML 26.2 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean HTML 27.6 KB
2025-06-30 00:00
[기재정정]주식매수선택권부여에관한신고
Korean HTML 26.2 KB
2025-06-30 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.1 KB
2025-06-30 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.1 KB
2025-06-30 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.1 KB

Automate Your Workflow. Get a real-time feed of all Cellid Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellid Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellid Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alzinova AB Logo
Clinical-stage biopharma developing immunotherapies for Alzheimer's disease.
Sweden
ALZ
AMARIN CORP PLC\UK Logo
Develops and commercializes therapeutics to improve cardiovascular health.
United States of America
AMRN
AMGEN INC Logo
A biotechnology company developing human therapeutics for serious illnesses.
United States of America
AMGN
Industrial biotechnology company specializing in specialty enzymes and proteins.
South Korea
092040
AMICUS THERAPEUTICS, INC. Logo
Biotechnology company developing therapies for rare genetic and devastating diseases.
United States of America
FOLD
AMINOLOGICS CO.,LTD. Logo
Specialty manufacturer of high-purity chiral amino acids and their derivatives.
South Korea
074430
Amneal Pharmaceuticals, Inc. Logo
Develops, manufactures, and distributes generic and specialty pharmaceuticals.
United States of America
AMRX
Amphastar Pharmaceuticals, Inc. Logo
Develops, manufactures, and markets technically challenging medications.
United States of America
AMPH
Amylyx Pharmaceuticals, Inc. Logo
Develops therapies for neurodegenerative diseases and other unmet medical needs.
United States of America
AMLX
AN2 Therapeutics, Inc. Logo
Biopharmaceutical firm developing boron-based drugs for infectious diseases.
United States of America
ANTX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.